AU2017429312B2 - Uses of cannabidiol in preparation of drugs for resisting against influenza - Google Patents

Uses of cannabidiol in preparation of drugs for resisting against influenza Download PDF

Info

Publication number
AU2017429312B2
AU2017429312B2 AU2017429312A AU2017429312A AU2017429312B2 AU 2017429312 B2 AU2017429312 B2 AU 2017429312B2 AU 2017429312 A AU2017429312 A AU 2017429312A AU 2017429312 A AU2017429312 A AU 2017429312A AU 2017429312 B2 AU2017429312 B2 AU 2017429312B2
Authority
AU
Australia
Prior art keywords
influenza
cannabidiol
group
virus
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017429312A
Other languages
English (en)
Other versions
AU2017429312A1 (en
Inventor
Xiangdong Li
Xin Tan
Zhaohui Yu
Ke Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanyi Bio-Technology Co Ltd
Original Assignee
Hanyi Bio-Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanyi Bio-Technology Co Ltd filed Critical Hanyi Bio-Technology Co Ltd
Publication of AU2017429312A1 publication Critical patent/AU2017429312A1/en
Application granted granted Critical
Publication of AU2017429312B2 publication Critical patent/AU2017429312B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017429312A 2017-08-31 2017-08-31 Uses of cannabidiol in preparation of drugs for resisting against influenza Ceased AU2017429312B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/099956 WO2019041239A1 (zh) 2017-08-31 2017-08-31 大麻二酚在制备抗流感的药物中的用途

Publications (2)

Publication Number Publication Date
AU2017429312A1 AU2017429312A1 (en) 2020-04-16
AU2017429312B2 true AU2017429312B2 (en) 2022-03-24

Family

ID=65524611

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017429312A Ceased AU2017429312B2 (en) 2017-08-31 2017-08-31 Uses of cannabidiol in preparation of drugs for resisting against influenza

Country Status (6)

Country Link
US (1) US11452707B2 (enExample)
EP (1) EP3677258B1 (enExample)
JP (1) JP6963719B2 (enExample)
AU (1) AU2017429312B2 (enExample)
CA (1) CA3073576C (enExample)
WO (1) WO2019041239A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113116867B (zh) * 2019-12-31 2022-08-23 汉义生物科技（北京）有限公司 一种预防和/或治疗流感的组合物
CN111249266B (zh) * 2020-03-06 2022-08-09 中国人民解放军海军军医大学 帕拉米韦在制备治疗感染性疾病引起炎症风暴的药物中的应用
DK181405B1 (en) * 2021-05-25 2023-10-17 Cs Medica As Gel for Intranasal Application, its Provision and Use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065079A2 (en) * 2008-11-25 2010-06-10 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2012012498A9 (en) * 2010-07-20 2012-04-05 Pulmatrix, Inc. Use of trp channel agonists to treat infections
US20130012502A1 (en) * 2009-12-09 2013-01-10 Hospices Civils De Lyon Pharmaceutical or Veterinary Antiviral Compositions
CN103282021A (zh) * 2010-10-29 2013-09-04 比蔻匹亚有限公司 炎症性疾病
CN103391768A (zh) * 2011-02-04 2013-11-13 比蔻匹亚有限公司 治疗慢性炎症和炎性疾病的组合物和方法
WO2017218845A1 (en) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Methods and compositions for reducing oxidative stress

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308213B2 (en) * 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
US20160317468A1 (en) * 2015-04-28 2016-11-03 Raman Sankar Uses of cannabidiol for treatment of infantile spasms
CA2985969A1 (en) * 2015-05-13 2016-11-17 One World Cannabis Ltd Use of cannabis to treat fibromyalgia, methods and compositions thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065079A2 (en) * 2008-11-25 2010-06-10 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US20130012502A1 (en) * 2009-12-09 2013-01-10 Hospices Civils De Lyon Pharmaceutical or Veterinary Antiviral Compositions
WO2012012498A9 (en) * 2010-07-20 2012-04-05 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CN103282021A (zh) * 2010-10-29 2013-09-04 比蔻匹亚有限公司 炎症性疾病
CN103391768A (zh) * 2011-02-04 2013-11-13 比蔻匹亚有限公司 治疗慢性炎症和炎性疾病的组合物和方法
WO2017218845A1 (en) * 2016-06-15 2017-12-21 Ojai Energetics Pbc Methods and compositions for reducing oxidative stress

Also Published As

Publication number Publication date
EP3677258A4 (en) 2020-09-09
JP2020530499A (ja) 2020-10-22
EP3677258A1 (en) 2020-07-08
CA3073576A1 (en) 2019-03-07
JP6963719B2 (ja) 2021-11-10
WO2019041239A1 (zh) 2019-03-07
US11452707B2 (en) 2022-09-27
CA3073576C (en) 2023-01-24
EP3677258B1 (en) 2022-02-09
AU2017429312A1 (en) 2020-04-16
US20200360336A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
KR102607599B1 (ko) 인플루엔자의 치료 방법
Jin et al. Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs
Wang et al. Inhibition of the infectivity and inflammatory response of influenza virus by Arbidol hydrochloride in vitro and in vivo (mice and ferret)
KR100962334B1 (ko) 울금으로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제
Galabov et al. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice
KR100950445B1 (ko) 감초로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제
KR101782532B1 (ko) 백지 추출물 또는 이로부터 분리된 퓨라노쿠마린을 함유하는 조류 인플루엔자, 돼지 인플루엔자 또는 코로나 바이러스의 예방 또는 치료용 조성물
CA3073576C (en) Use of cannabidiol in preparation of drugs for resisting against influenza
WO2022228651A1 (en) Pyruvate esters for the treatment of viral diseases
CN109419786B (zh) 大麻二酚在制备抗流感的药物中的用途
Sun et al. Sodium taurocholate hydrate inhibits influenza virus replication and suppresses influenza a Virus-triggered inflammation in vitro and in vivo
US11433080B2 (en) Antiviral treatment
KR101731607B1 (ko) 음양곽 추출물을 유효성분으로 함유하는 항 바이러스용 조성물
Yu Efficacy of (R)-6-adamantane-derivatives of 1, 3-oxazinan-2-one and piperidine-2, 4-dione in the treatment of mice infected by the A/California/04/2009 influenza virus
KR20230123906A (ko) 선학초(Agrimonia pilosa) 추출물과 오배자(Galla rhois)추출물의 혼합물을 유효성분으로 포함하는 인플루엔자 바이러스 감염증 예방, 치료 또는 개선용 조성물
Sow et al. Inhibition of influenza A virus by salvianolic acid C targeting neuraminidase and phosphorylated-STAT3
EP4108241A1 (en) Anti-rna virus drug and application thereof
CN114288297A (zh) 千金藤素在制备抗流感病毒药物中的应用
CN104857007A (zh) 一种流感病毒神经氨酸酶的新型抑制剂及其用途
KR102693277B1 (ko) 인플루엔자 바이러스 감염의 예방 또는 치료용 조성물
CN110151767B (zh) Gnf-7在制备治疗流感病毒感染的药物中的应用
KR20230146695A (ko) 인플루엔자 바이러스 억제용 조성물
CN117838698A (zh) 奥拉替尼在制备治疗流感病毒感染的药物中的应用
KR20230039782A (ko) 선학초(Agrimonia pilosa) 추출물과 오배자(Galla rhois) 추출물의 혼합물을 유효성분으로 포함하는 인플루엔자 바이러스 감염증 예방, 치료 또는 개선용 조성물
WO2020216349A1 (zh) 一种肠道病毒抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired